Company Silo Pharma, Inc.

SILO

US82711P2011

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Silo Pharma, Inc.

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-09 EDT			5-day change	1st Jan Change
1.76 ^USD	-2.22%		-4.86%	+22.22%

04-23	Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment	CI
04-10	Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University	MT

Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Companyâs lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimerâs disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).

Number of employees: 3

USD in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical 100.0 %	0	100.0 %	0	100.0 %	0.00%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	0	100.0 %	0.00%

Managers	Title	Age	Since
Eric Weisblum CEO	Chief Executive Officer	54	10-07-12
Daniel Ryweck DFI	Director of Finance/CFO	59	22-09-26
James Kuo CTO	Chief Tech/Sci/R&D Officer	58	22-08-31

Members of the board	Title	Age	Since
Eric Weisblum CEO	Chief Executive Officer	54	10-07-12
Wayne Linsley BRD	Director/Board Member	67	20-01-15
Kevin Muñoz BRD	Director/Board Member	46	20-09-30
Jeff Pavell BRD	Director/Board Member	57	22-09-26

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,096,489	2,663,202 ( 86.01 %)	252,855 ( 8.166 %)	86.01 %

Name	Equities	%	Valuation
Eric Weisblum 6.169 %	175,432	6.169 %	342 092 $
Scott Wilfong 3.794 %	107,876	3.794 %	210 358 $
Financial Advocates Investment Management LLC 2.209 %	62,807	2.209 %	122 474 $
UBS Securities LLC 1.155 %	32,843	1.155 %	64 044 $
Vanguard Group, Inc. (Subfiler) 0.5744 %	16,334	0.5744 %	31 851 $
Geode Capital Management LLC 0.5690 %	16,179	0.5690 %	31 549 $
Two Sigma Securities LLC 0.4497 %	12,788	0.4497 %	24 937 $
STATE STREET CORPORATION 0.4396 %	12,500	0.4396 %	24 375 $
Tower Research Capital LLC 0.2464 %	7,007	0.2464 %	13 664 $
Daniel Ryweck 0.1758 %	5,000	0.1758 %	9 750 $

Silo Pharma, Inc.

677 North Washington Boulevard

34236, Sarasota

http://www.silopharma.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.76 USD

Average target price

10 USD

Spread / Average Target

+468.18%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
SILO PHARMA, INC.	+22.22%	5M
CSL LIMITED	-2.61%	88.47B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.71B
BIOGEN INC.	-13.92%	32.43B
UCB	+54.75%	24.28B
BIOMARIN PHARMACEUTICAL INC.	-15.25%	15.52B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	12.17B
INCYTE CORPORATION	-14.80%	12.01B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	12B
SWEDISH ORPHAN BIOVITRUM AB	+7.64%	8.87B

Biopharmaceuticals